drugset / Trial / NCT05769959
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
NaSequentialOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
Timeline
- Start
- 2023-06-15
- Primary completion
- 2024-03-19
- Completion
- 2024-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RO7515629 | Unknown | — | Intravenous |
| Background | Tocilizumab | Monoclonal antibody | — | — |